VDR Genotype

Two people can take the same vitamin D dose, hit the same blood level, and still get very different results in bone, immune, and inflammatory measures. Part of that difference lives in your DNA, specifically in the gene that builds your cells' vitamin D docking station.

VDR (vitamin D receptor) genotype reads inherited variants such as FokI, BsmI, ApaI, and TaqI from a cheek swab. The result is a one-time look at how your cells may respond to vitamin D, useful as background context for vitamin D testing, supplementation decisions, and certain disease conversations.

What This Test Actually Reads

Your buccal swab collects cheek cells, which are an easy source of your inherited DNA. A lab then looks at specific spots in the VDR gene on chromosome 12 (band 12q13.11), most often FokI, BsmI, ApaI, and TaqI. The result is a categorical genotype call (for example, CC, CT, or TT at a given spot), not a level that rises or falls.

The VDR protein itself is made in many tissues, including intestine, bone, kidney, placenta, pancreas, skin, immune cells, vascular smooth muscle, endothelium, heart muscle cells, and platelets. When active vitamin D binds VDR, the receptor pairs with another protein called RXR and switches target genes on or off. Your genotype reflects inherited differences in that signaling capacity. FokI sits at the protein's start site and can produce a slightly shorter receptor. ApaI, BsmI, and TaqI are usually silent on their own and tend to act as markers for other nearby functional changes.

Bone, Mineral, and Vitamin D Response

VDR signaling contributes to calcium and phosphate balance and bone mineralization, in part through its regulation of the FGF23 and Klotho pathways that are central to phosphate handling. This is the cleanest mechanistic territory for the receptor, and rare severe VDR mutations cause hereditary vitamin D resistant rickets with hair loss.

For common variants, the strongest practical signal is in how people respond to vitamin D supplementation. A meta-analysis of vitamin D supplementation trials reported that the variant allele (Tt+tt) of TaqI and the FF genotype of FokI were associated with a better response to vitamin D supplementation (p = 0.02 and p less than 0.001), while BsmI and ApaI did not significantly modify response. In one human study, FokI and TaqI genotypes were independent determinants of VDR mRNA and VDR protein levels in immune cells, along with insulin secretory capacity.

For postmenopausal osteoporosis specifically, pooled evidence is null. A 22-study meta-analysis of ApaI found no overall association with postmenopausal osteoporosis in either Asian or Caucasian women. So while VDR signaling clearly matters for bone biology, common VDR variants are not a screening test for bone disease.

Infection and Inflammation

Vitamin D signaling helps shape how your immune system handles certain microbes, and some variants track with infection risk. A meta-analysis of tuberculosis studies found that the FokI ff homozygote model was associated with about 1.32 times the risk of TB compared to FF (ORff vs. FF = 1.32, 95%CI 1.03 to 1.69), with a stronger signal in Asian populations (about 1.57 times the risk, ORff vs. FF = 1.57, 95%CI 1.12 to 2.21).

For viral infection, a meta-analysis of enveloped viruses found FokI significantly associated with respiratory syncytial virus (RSV) infection. In multidrug-resistant tuberculosis, the picture is less clear; reviewers describe vitamin D status and common VDR variants as plausibly shaping host immunity but with limited and mixed evidence for treatment response and prognosis.

For day-to-day inflammation, one orthopedic study of 500 patients linked the rs2228570 (FokI) TT genotype to higher C-reactive protein (about 11 mg/L higher, beta = 10.90, p = 0.00329), higher quality-of-life scores on SF-36 (beta = 6.31, p = 0.00009), and modest differences in white blood cell, lymphocyte, hemoglobin, and hematocrit values. A companion study of rs7975232 (ApaI) found the CC genotype was associated with higher neutrophil counts (p = 0.029) and the AA genotype with elevated CRP (p = 0.025). These are research-grade signals, not diagnostic cutoffs.

Cardiovascular and Pregnancy Outcomes

Because VDR is expressed in vascular smooth muscle, endothelium, heart muscle cells, and platelets, several studies have looked at cardiovascular phenotypes. In a Bangladeshi cohort, vitamin D deficiency together with FokI variants was associated with increased susceptibility to high blood pressure. A separate cardiovascular study found the FokI TT genotype linked to higher rates of heart failure and high blood pressure, and ApaI TT, TaqI TC, and BsmI GA genotypes to higher obesity risk.

For high blood pressure conditions during pregnancy, a systematic review found that 4 of 9 studies reported an association between the FokI variant and hypertensive disorders of pregnancy in Asian populations, while TaqI was not associated across the populations studied. The pattern matters: these associations are population specific and often interact with vitamin D status.

Cognitive and Metabolic Associations

A meta-analysis of cognitive outcomes reported that the BsmI variant was associated with about 1.77 times the odds of mild cognitive impairment in the allelic model (OR 1.77, 95% CI 1.24 to 2.54) and about 2.04 times in the dominant model (OR 2.04, 95% CI 1.32 to 3.16). For Alzheimer disease, the TaqI dominant model showed about 1.44 times the odds (OR 1.44, 95% CI 1.17 to 1.79), particularly in Caucasian populations.

For metabolic disease overall, a 28-study meta-analysis covering 9,232 participants found no significant overall association between ApaI, BsmI, FokI, or TaqI and insulin-resistance-related disease. Subgroup signals appeared in Asians and at certain latitudes, but the headline is that VDR genotype is not a reliable screening tool for insulin resistance.

More recent pharmacogenomic evidence suggests genotype may still flag who benefits from supplementation. A 2026 analysis of the D2d trial reported that the ApaI polymorphism identified which adults with prediabetes benefited from vitamin D supplementation for diabetes prevention: those with AC or CC genotypes had about a 19% reduction in diabetes risk, while AA carriers showed no benefit. This is an early but directly relevant finding for using VDR genotype to personalize vitamin D decisions.

Cancer Associations

Cancer evidence is uneven. A meta-analysis of multiple myeloma found that TaqI, ApaI, BsmI, and FokI were associated with risk in Asian populations, with FokI showing one of the larger effects (about 2.83 times the odds for TT vs. CC, OR 2.829, 95% CI 2.066 to 3.872). A separate systematic review in European-ancestry populations concluded there was insufficient evidence to confirm a VDR-myeloma link, so the signal is ancestry-specific.

For colorectal cancer, the evidence is genuinely mixed rather than settled. One recent meta-analysis across 24 datasets found no significant associations for any of the four common VDR variants. Other meta-analyses, however, have reported significant associations, particularly for BsmI, with colorectal cancer risk. The fairest read is that common VDR variants are not a clear-cut biomarker for colorectal cancer susceptibility and should not be used as one in isolation.

For oral cancer, an updated systematic review describes the evidence as promising but early, with effects shaped by environmental and lifestyle factors including smoking, alcohol, sun exposure, diet, and vitamin D status. Translation: VDR genotype is not a stand-alone cancer screening test.

Resolving the Mixed Picture

It can feel contradictory that the same variant is linked to higher TB risk in one analysis, no insulin resistance in another, and a better vitamin D supplementation response in a third. The resolution is that VDR genotype is not a single number with a single meaning. It is a stable signaling setting that interacts with your environment, your vitamin D status, your ancestry, and the specific disease pathway in question. Several studies note that associations between VDR genotype and conditions like rickets, colorectal cancer, tuberculosis, hepatitis B, and leprosy are more pronounced in people with vitamin D deficiency or in populations where deficiency is common. Genotype is one input among many, not a verdict.

Your One-Time Result

VDR genotype is fixed at conception and does not change over your lifetime, so this test is a one-and-done measurement. There is no trend to track in your VDR result itself. The value comes from integrating it into the labs and decisions you make over the years.

What does benefit from repeat tracking are the dynamic markers around it. Your serum 25-hydroxy vitamin D, calcium, and PTH (parathyroid hormone) are the numbers worth retesting on a standard vitamin D monitoring schedule, regardless of genotype: typically a baseline check, a repeat about 3 months after starting or changing supplementation, and at least annually thereafter. Inflammatory markers like hs-CRP (high-sensitivity C-reactive protein) and a CBC (complete blood count) can be retested on the same yearly schedule for context, especially if your VDR genotype carries an inflammation-linked variant.

When Results Can Be Misleading

Genetic tests have their own confounders, and these are different from the lifestyle confounders that affect dynamic biomarkers.

• Panel coverage: this test reads specific VDR variants such as FokI, BsmI, ApaI, and TaqI. A negative result does not rule out rarer or unlisted variants in the same gene that the assay does not look at.
• Ancestry-specific frequencies: many VDR associations are stronger in some populations and absent in others. A finding from a Chinese, Iranian, or Caucasian cohort does not automatically apply to your background.
• Direct-to-consumer reports: clinical-grade buccal genotyping uses validated platforms like TaqMan, PCR-RFLP, or MassARRAY. Results from a 23andMe-style chip for the same spot may report a different format and are not always equivalent for clinical interpretation.
• Variants of uncertain meaning: an unusual call may be flagged with unclear clinical significance, particularly outside the four most-studied variants.

What to Do With an Unexpected Result

VDR genotype does not require an emergency response. It belongs in a longer conversation. If your result flags a variant linked to a stronger response to vitamin D supplementation, the next move is checking serum 25-hydroxy vitamin D and following it as you adjust intake. If it flags a variant linked to higher inflammatory tone or high blood pressure risk in studies, pair it with hs-CRP, blood pressure tracking, and a lipid panel rather than treating the gene alone.

For variants tied to bone phenotypes, the companion workup is serum calcium, PTH, vitamin D, and bone density imaging at the screening intervals appropriate for your age and sex. If the result lands in unfamiliar territory or you carry a strong family history of related conditions, a genetic counselor or endocrinologist can put it in context. The action point is rarely the genotype itself; it is the dynamic phenotype testing the genotype encourages you to do more proactively.

What the Result Means for Your Family

Because VDR variants are inherited, your result has implications for biological relatives. First-degree family members (parents, siblings, children) share roughly half of your DNA on average and have meaningful odds of carrying the same variants. Sharing your result with them, particularly if they are weighing decisions about vitamin D supplementation, bone health monitoring, or pregnancy planning in the case of variants linked to high blood pressure during pregnancy, gives them useful context for their own testing choices.